Review of risk factors and surgical treatment progress for gallbladder cancer

Jianguo Feng, Haihong Zhu, Xiaosong WangHereditas 2025 · DOI

TL;DR

This review synthesizes the latest evidence on gallbladder cancer (GBC) risk factors and surgical treatment, highlighting current controversies and emerging therapeutic avenues like targeted and immunotherapy. It emphasizes the need for a comprehensive strategy, including early screening and individualized multimodal treatment, to improve patient outcomes.

What Problem Does This Paper Address?

Gallbladder cancer (GBC) is a challenging malignancy characterized by insidious onset, late diagnosis, and poor prognosis, with surgery being the only potentially curative option. However, significant controversies persist regarding the optimal surgical extent, especially for advanced stages, and the integration of novel therapies. This paper aims to systematically review the current understanding of GBC risk factors, analyze the ongoing debates in surgical management, and explore the potential of molecularly targeted and immunotherapies to address these challenges and guide future clinical practice and research.

Methods

This paper is a comprehensive review of existing literature. The authors retrieved and analyzed studies published between 2018 and 2024 from major databases (PubMed, Web of Science, and CNKI). The methodology involved summarizing, comparing, and critically analyzing the retrieved literature on GBC risk factors, molecular mechanisms, and treatment strategies.

Datasets

Not discussed in the paper. This is a review article, not an empirical study that collected or analyzed specific datasets.

Key Insights and Ideas

  • Multifactorial Etiology: GBC development is a complex interplay of genetic predisposition, environmental exposures, and metabolic factors.
  • Key Genetic Drivers: Mutations in TP53 and ERBB2/ERBB3 genes are significant, impacting apoptosis and immune escape mechanisms. ERBB2, in particular, shows promise as a predictive biomarker for immunotherapy.
  • Metabolic Syndrome as a Risk Factor: Obesity, hyperglycemia, and hyperlipidemia are increasingly recognized as significant contributors to GBC risk, likely through mechanisms involving insulin resistance and inflammation.
  • Surgical Controversies Persist: Despite advances, debates continue regarding the necessity and extent of hepatic resection for early-stage tumors (T1b) and the oncological safety of laparoscopic approaches for more advanced stages (T2).
  • Emerging Targeted and Immunotherapies: Molecularly targeted agents (e.g., against ERBB2, NTRK) and immune checkpoint inhibitors (anti-PD-1/PD-L1) are showing promise in advanced GBC, offering new hope beyond traditional chemotherapy.
  • Need for Individualized Treatment: A comprehensive strategy involving risk stratification, precise staging, and tailored multimodal treatment is crucial for combating GBC.

Key Results

  • Risk Factors Identified: Beyond gallstones and polyps, significant risk factors include TP53 and ERBB2/ERBB3 gene mutations, metabolic syndrome components (obesity, hyperglycemia, hyperlipidemia), and chronic infections (Salmonella, Helicobacter).
  • Surgical Staging and Recommendations:
    • Tis/T1a stage: Simple cholecystectomy is generally sufficient.
  • T1b/T2 stage: Radical cholecystectomy with hepatic wedge resection and regional lymph node dissection is often recommended, though controversies exist regarding the extent and approach (laparoscopic vs. open).
  • T3/T4 stage: Treatment becomes more complex, with debates on the role of extended radical resection and the high morbidity associated with procedures like hepatopancreatoduodenectomy (HPD).
  • Therapeutic Advances:
    • Chemotherapy combined with immunotherapy (e.g., durvalumab with gemcitabine and cisplatin) has significantly improved survival in advanced GBC.
  • Various targeted therapies are emerging for specific molecular alterations (e.g., FGFR2 fusions, NTRK fusions, IDH1 mutations, HER2 amplification).

Limitations and Future Work

  • Limitations: The paper acknowledges the lack of high-level evidence, particularly from prospective randomized controlled trials, to resolve many surgical controversies. The conceptual distinction between neoadjuvant and conversion therapy also poses challenges for clinical study design.
  • Future Work:
    • Risk Stratification: Develop predictive models integrating molecular biomarkers (ctDNA), imaging, and clinical factors for early diagnosis in high-risk populations.
  • Standardization of Minimally Invasive Surgery: Conduct prospective, multicenter randomized controlled trials to establish standardized and evidence-based practices for laparoscopic surgery in T1b/T2 stages.
  • Multimodal Integrated Therapy: Explore optimal combinations of neoadjuvant/adjuvant therapies with surgery, clarifying patient selection and timing for immunotherapy and targeted therapy.
  • Basic and Translational Research: Deepen understanding of the tumor microenvironment (TME) to identify novel therapeutic targets.
  • Molecular Subtyping: Build prognostic models based on molecular subtypes to guide individualized treatment.

Summary updated

Abstract

Combating GBC requires a comprehensive strategy encompassing health education, screening of high-risk populations, precise staging, and individualized multimodal treatment. Future research should focus on building molecular subtype-based prognostic models, conducting high-level clinical studies to resolve surgical controversies, and exploring the integration of novel adjuvant therapies with traditional surgery.
BibTeX
@inproceedings{feng2025review,
  author = {Jianguo Feng and Haihong Zhu and Xiaosong Wang},
  title = {{Review of risk factors and surgical treatment progress for gallbladder cancer}},
  booktitle = {Hereditas},
  year = {2025},
  doi = {10.1186/s41065-025-00608-z},
}
Figure